110 related articles for article (PubMed ID: 8848823)
1. Phenobarbital induces the 2-hydroxylation of desipramine.
Spina E; Avenoso A; Campo GM; Caputi AP; Perucca E
Ther Drug Monit; 1996 Feb; 18(1):60-4. PubMed ID: 8848823
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo.
von Moltke LL; Greenblatt DJ; Duan SX; Daily JP; Harmatz JS; Shader RI
J Pharm Sci; 1998 Oct; 87(10):1184-9. PubMed ID: 9758674
[TBL] [Abstract][Full Text] [Related]
3. The effect of carbamazepine on the 2-hydroxylation of desipramine.
Spina E; Avenoso A; Campo GM; Caputi AP; Perucca E
Psychopharmacology (Berl); 1995 Feb; 117(4):413-6. PubMed ID: 7604141
[TBL] [Abstract][Full Text] [Related]
4. Polymorphic 2-hydroxylation of desipramine. A population and family study.
Dahl ML; Iselius L; Alm C; Svensson JO; Lee D; Johansson I; Ingelman-Sundberg M; Sjöqvist F
Eur J Clin Pharmacol; 1993; 44(5):445-50. PubMed ID: 8359181
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population.
Dahl ML; Johansson I; Palmertz MP; Ingelman-Sundberg M; Sjöqvist F
Clin Pharmacol Ther; 1992 Jan; 51(1):12-7. PubMed ID: 1346258
[TBL] [Abstract][Full Text] [Related]
6. Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population.
Marandi T; Dahl ML; Kiivet RA; Rägo L; Sjöqvist F
Pharmacol Toxicol; 1996 May; 78(5):303-7. PubMed ID: 8737964
[TBL] [Abstract][Full Text] [Related]
7. Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects.
Spina E; Avenoso A; Campo GM; Scordo MG; Caputi AP; Perucca E
Br J Clin Pharmacol; 1997 Mar; 43(3):315-8. PubMed ID: 9088587
[TBL] [Abstract][Full Text] [Related]
8. Effects of desvenlafaxine on the pharmacokinetics of desipramine in healthy adults.
Nichols AI; Abell M; Chen Y; Behrle JA; Frick G; Paul J
Int Clin Psychopharmacol; 2013 Mar; 28(2):99-105. PubMed ID: 23221858
[TBL] [Abstract][Full Text] [Related]
9. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study.
Spina E; Gitto C; Avenoso A; Campo GM; Caputi AP; Perucca E
Eur J Clin Pharmacol; 1997; 51(5):395-8. PubMed ID: 9049581
[TBL] [Abstract][Full Text] [Related]
10. Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents.
LLerena A; Herraíz AG; Cobaleda J; Johansson I; Dahl ML
Clin Pharmacol Ther; 1993 Dec; 54(6):606-11. PubMed ID: 7903915
[TBL] [Abstract][Full Text] [Related]
11. Difference in desipramine metabolic profile between wild-type and CYP2D6-humanized mice.
Shen HW; Yu AM
Drug Metab Lett; 2009 Dec; 3(4):234-41. PubMed ID: 19995332
[TBL] [Abstract][Full Text] [Related]
12. Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype.
Spina E; Steiner E; Ericsson O; Sjöqvist F
Clin Pharmacol Ther; 1987 Mar; 41(3):314-9. PubMed ID: 3816019
[TBL] [Abstract][Full Text] [Related]
13. Urinary desipramine hydroxylation index and steady-state plasma concentrations of imipramine and desipramine.
Spina E; Arena A; Pisani F
Ther Drug Monit; 1987 Jun; 9(2):129-33. PubMed ID: 3617150
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes.
Spina E; Birgersson C; von Bahr C; Ericsson O; Mellström B; Steiner E; Sjöqvist F
Clin Pharmacol Ther; 1984 Nov; 36(5):677-82. PubMed ID: 6488689
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
16. Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics.
Laine K; De Bruyn S; Björklund H; Rouru J; Hänninen J; Scheinin H; Anttila M
Eur J Clin Pharmacol; 2004 Feb; 59(12):893-8. PubMed ID: 14730412
[TBL] [Abstract][Full Text] [Related]
17. Electrocardiographic effects of desipramine and 2-hydroxydesipramine in children, adolescents, and adults treated with desipramine.
Wilens TE; Biederman J; Baldessarini RJ; Puopolo PR; Flood JG
J Am Acad Child Adolesc Psychiatry; 1993 Jul; 32(4):798-804. PubMed ID: 8340301
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of desipramine 2-hydroxylation by quinidine and quinine.
Steiner E; Dumont E; Spina E; Dahlqvist R
Clin Pharmacol Ther; 1988 May; 43(5):577-81. PubMed ID: 3365919
[TBL] [Abstract][Full Text] [Related]
19. Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics.
Furman KD; Grimm DR; Mueller T; Holley-Shanks RR; Bertz RJ; Williams LA; Spear BB; Katz DA
Pharmacogenetics; 2004 May; 14(5):279-84. PubMed ID: 15115913
[TBL] [Abstract][Full Text] [Related]
20. Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6.
Bergmann TK; Bathum L; Brosen K
Eur J Clin Pharmacol; 2001 May; 57(2):123-7. PubMed ID: 11417443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]